多弹头射频消融联合干扰素α治疗肝癌的临床研究  

Clinical study on combination of RFA and INFα in treatment of hepatocellular carcinoma

作　　者：许颖[1] 姜振宇[1] 姚程[1] 赵恒军[1] 李薇[1] 

机构地区：[1]吉林大学第一临床医院血液肿瘤科,吉林长春130021

出　　处：《中国老年学杂志》2007年第3期257-258,共2页Chinese Journal of Gerontology

基　　金：吉林省科技厅资助项目(200505202)

摘　　要：目的探讨多弹头射频消融(RFA)联合干扰素(INF)α治疗肝癌的临床效果。方法手术组(n=29)和接受RFA治疗患者(n=58),其中RFA组29例单纯接受RFA治疗和联合组29例接受RFA治疗+INFα治疗,分析与比较各组的生存率、复发率及复发相关因素。结果手术组、RFA组及联合组1年生存率分别为85.72%、90.89%、93.45%,2年生存率分别为67.69%、75.19%、80.02%,3年累积生存率分别为46.52%、53.69%、61.74%。手术组、RFA组及联合组1年复发率分别为28.63%、20.59%、15.19%,3年复发率分别为35.35%、30.77%、23.91%。RFA组与联合组生存率及复发率差异有显著性(P<0.05)。RFA治疗后是否应用INFα治疗是影响复发的独立因素,RFA后应用INFα复发率可减低2.267倍。结论多弹头RFA联合INFα治疗肝癌可明显提高患者的生存率,降低复发率。Objective To observe the clinical effect in patients with hepatocellular carcinoma （HCC） after radiofrequency ablation （RFA） combined with INFα. Methods 58 HCC patients were divided into 29 RFA treatment cases （RFA group） and 29 RFA combined with INFα （ combination group）. The surgery group included 29 cases. The differences of survival rate and relapse rate among the RFA, RFA ＋ INFα and surgery group were compared. Results The 1-year survival rate of surgery group, RFA group and combination group was 85. 72% ,90. 89% ,93.45% respectively. The 2-year survival rate was 67. 69% ,75.19% ,80. 02% respectively. The 3-year survival rate was 46. 52% ,53. 69%, 61.74% respectivdy. The 1-year relapse rate of surgery group, RFA group and combination group was 28. 63%, 20. 59% ,15. 19% respectivdy. The 3-year relapse rate was 35.35% ,30. 77% ,23.91% respectively. There was significant difference in survival and relapse rate between RFA group and combination group. Conclusions RFA combined with INFα can improve the survival rate and decrease the relapse rate in HCC patients.

关 键 词：多弹头射频 肝癌 干扰素Α 

分 类 号：R735.7[医药卫生—肿瘤]